MCL1 and lymphoma: The tide has turned and a number of robust BH3 mimetic drugs targeting MCL-1 are now available; Abbvie's A1210477 potently inhibits MCL-1 in vitro to restrict growth of diverse cancer cell lines [134,135], UMI-77 inhibits pancreatic and breast cancer cell line growth in vitro and in vivo [96,136], and the Servier compound S63845 seems particularly potent, with on-target single agent killing of leukaemia and lymphoma models in vitro and in vivo [4] and in combination with conventional cancer therapy in xenograft models of breast cancer [137].